Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership

Reuters10-29

Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership

Fangzhou Inc., a leader in AI-driven Internet healthcare solutions, has entered into a strategic collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance AI-powered psoriasis management. The partnership will leverage Fangzhou's proprietary AI technologies, including its "XingShi" Large Language Model and AI Health Manager, alongside Fosun Pharma's expertise and products such as Otezla® for psoriasis treatment. Together, the companies aim to develop a comprehensive digital health platform that offers personalized care, medication guidance, and ongoing support for patients with psoriasis and other autoimmune conditions. The initiative is designed to improve long-term disease management and support the goals of the Healthy China 2030 initiative.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fangzhou Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564300-en) on October 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579973126?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 17:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579973126","market":"us","top_or_hot":-1,"title":"Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fangzhou Inc., a leader in AI-driven Internet healthcare solutions, has entered into a strategic collaboration with <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (Fosun Pharma) to advance AI-powered psoriasis management. The partnership will leverage Fangzhou's proprietary AI technologies, including its \"XingShi\" Large Language Model and AI Health Manager, alongside Fosun Pharma's expertise and products such as Otezla® for psoriasis treatment. Together, the companies aim to develop a comprehensive digital health platform that offers personalized care, medication guidance, and ongoing support for patients with psoriasis and other autoimmune conditions. The initiative is designed to improve long-term disease management and support the goals of the Healthy China 2030 initiative.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fangzhou Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564300-en) on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-29 17:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Fangzhou Inc., a leader in AI-driven Internet healthcare solutions, has entered into a strategic collaboration with <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (Fosun Pharma) to advance AI-powered psoriasis management. The partnership will leverage Fangzhou's proprietary AI technologies, including its \"XingShi\" Large Language Model and AI Health Manager, alongside Fosun Pharma's expertise and products such as Otezla® for psoriasis treatment. Together, the companies aim to develop a comprehensive digital health platform that offers personalized care, medication guidance, and ongoing support for patients with psoriasis and other autoimmune conditions. The initiative is designed to improve long-term disease management and support the goals of the Healthy China 2030 initiative.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fangzhou Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564300-en) on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL7l9Wmt:1","article_id":"2579973126","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579973126","pubTimestamp":1761731804,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Fangzhou Inc., a leader in AI-driven Internet healthcare solutions, has entered into a strategic collaboration with Shanghai Fosun Pharmaceutical  to advance AI-powered psoriasis management. The partnership will leverage Fangzhou's proprietary AI technologies, including its \"XingShi\" Large Language Model and AI Health Manager, alongside Fosun Pharma's expertise and products such as Otezla for psoriasis treatment. Together, the companies aim to develop a comprehensive digital health platform that offers personalized care, medication guidance, and ongoing support for patients with psoriasis and other autoimmune conditions. The initiative is designed to improve long-term disease management and support the goals of the Healthy China 2030 initiative.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","BK0183":"MSCI概念","BK0188":"融资融券","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK0012":"证金概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK0187":"一线龙头","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK0028":"国家队","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK0175":"白马股","BK0060":"抗癌","BK1230":"工业集团企业","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK0096":"民营医院","BK4585":"ETF&股票定投概念","BK0196":"行业龙头","BK1247":"药品零售","BK0239":"医药制造","00656":"复星国际","06086":"方舟健客"},"translate_title":"方舟与复星医药启动AI驱动的银屑病管理合作伙伴关系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"NDAQ":0.9,"00656":0.9,"06086":0.9},"content_text":"Fangzhou and Fosun Pharma Launch AI-Powered Psoriasis Management Partnership\n    \n\n        Fangzhou Inc., a leader in AI-driven Internet healthcare solutions, has entered into a strategic collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance AI-powered psoriasis management. The partnership will leverage Fangzhou's proprietary AI technologies, including its \"XingShi\" Large Language Model and AI Health Manager, alongside Fosun Pharma's expertise and products such as Otezla® for psoriasis treatment. Together, the companies aim to develop a comprehensive digital health platform that offers personalized care, medication guidance, and ongoing support for patients with psoriasis and other autoimmune conditions. The initiative is designed to improve long-term disease management and support the goals of the Healthy China 2030 initiative.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fangzhou Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9564300-en) on October 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579973126","isCrawlerRequest":true}